Pathophysiology and treatment of pain in joint disease

Advanced Drug Delivery Reviews

Volumn 58, Issue 2, 2006, Pages 323-342

  Schaible, Hans Georg ^a   Schmelz, Martin ^b   Tegeder, Irmgard ^c  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

ASIC; CB; Hypersensitivity; Nociception; Opioids; Prostaglandin; Sensitization; TRPV

Indexed keywords

APPLICATION SPECIFIC INTEGRATED CIRCUITS; BIOELECTRIC POTENTIALS; CELL MEMBRANES; DRUG PRODUCTS; MEDICAL PROBLEMS; NEUROPHYSIOLOGY; PATHOLOGY; PATIENT TREATMENT; PROTEINS;

CB; HYPERSENSITIVITY; NOCICEPTION; OPIOIDS; PROSTAGLANDIN; SENSITIZATION; TRPV;

TENDONS;

ADALIMUMAB; ANANDAMIDE; ANTIINFLAMMATORY AGENT; CANNABINOID; CANNABINOID RECEPTOR AGONIST; CANNABIS; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE RECEPTOR ANTAGONIST; DRONABINOL; ETANERCEPT; FLURBIPROFEN; GLUCOCORTICOID; GOLD SALT; INFLIXIMAB; LICOFELONE; METHOTREXATE; MORPHINE 6 GLUCURONIDE; NAPROXEN; NITRIC OXIDE DONATING ASPIRIN; NITRIC OXIDE DONATING NAPROXEN; NITRIC OXIDE DONATING NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NITRIC OXIDE DONATING PARACETAMOL; NOCICEPTIN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PROSTAGLANDIN E2; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALICYLIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTHROPATHY; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; NERVE CELL EXCITABILITY; NEUROBIOLOGY; NEUROPATHIC PAIN; NOCICEPTION; NOCICEPTIVE RECEPTOR; NONHUMAN; OSTEOARTHRITIS; PAIN THRESHOLD; PATHOPHYSIOLOGY; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW; RHEUMATOID ARTHRITIS; SPINAL CORD DORSAL HORN; STOMACH INJURY; UNSPECIFIED SIDE EFFECT;

ANIMALS; ARTHRITIS; CENTRAL NERVOUS SYSTEM; HUMANS; JOINT DISEASES; PAIN; PERIPHERAL NERVOUS SYSTEM;

EID: 33748041976     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2006.01.011     Document Type: Review

References (226)

1. Millan M.J. The induction of pain: an integrative review. Prog. Neurobiol. 57 (1999) 1-164
2. Schaible H.G., and Grubb B.D. Afferent and spinal mechanisms of joint pain. Pain 55 (1993) 5-54
3. Lynn B. Neurogenic inflammation caused by cutaneous polymodal receptors. Prog. Brain Res. 113 (1996) 361-368
4. Holzer P. Neurogenic vasodilatation and plasma leakage in the skin. Gen. Pharmacol. 30 (1998) 5-11
5. Mense S. Nociception from skeletal muscle in relation to clinical muscle pain. Pain 54 (1993) 241-289
6. Weidner C., Schmelz M., Schmidt R., Hansson B., Handwerker H.O., and Torebjörk H.E. Functional attributes discriminating mechano-insensitive and mechano-responsive C nociceptors in human skin. J. Neurosci. 19 (1999) 10184-10190
7. Schmelz M., Schmidt R., Handwerker H.O., and Torebjörk H.E. Encoding of burning pain from capsaicin-treated human skin in two categories of unmyelinated nerve fibres. Brain 123 (2000) 560-571
8. Ringkamp M., Peng Y.B., Wu G., Hartke T.V., Campbell J.N., and Meyer R.A. Capsaicin responses in heat-sensitive and heat-insensitive A-fiber nociceptors. J. Neurosci. 21 (2001) 4460-4468
9. Schmelz M., Michael K., Weidner C., Schmidt R., Torebjörk H.E., and Handwerker H.O. Which nerve fibers mediate the axon reflex flare in human skin?. NeuroReport 11 (2000) 645-648
10. Klede M., Handwerker H.O., and Schmelz M. Central origin of secondary mechanical hyperalgesia. J. Neurophysiol. 90 (2003) 353-359
11. Weidner C., Schmelz M., Schmidt R., Hansson B., Handwerker H.O., and Torebjörk H.E. Functional attributes discriminating mechano-insensitive and mechano-responsive C nociceptors in human skin. J. Neurosci. 19 (1999) 10184-10190
12. Orstavik K., Weidner C., Schmidt R., Schmelz M., Hilliges M., Jørum E., Handwerker H., and Torebjörk H.E. Pathological C-fibres in patients with a chronic painful condition. Brain 126 (2003) 567-578
13. Bär K.J., Schurigt U., Scholze A., Segond V.B., Stopfel N., Bräuer R., Halbhuber K.J., and Schaible H.G. The expression and localization of somatostatin receptors in dorsal root ganglion neurons of normal and monoarthritic rats. Neuroscience 127 (2004) 197-206
14. Schaible H.G., Ebersberger A., and Von Banchet G.S. Mechanisms of pain in arthritis. Ann. N. Y. Acad. Sci. 966 343-54 (2002) 343-354
15. Carlton S.M., Du J., Zhou S., and Coggeshall R.E. Tonic control of peripheral cutaneous nociceptors by somatostatin receptors. J. Neurosci. 21 (2001) 4042-4049
16. Heppelmann B., and Pawlak M. Peripheral application of cyclo-somatostatin, a somatostatin antagonist, increases the mechanosensitivity of rat knee joint afferents. Neurosci. Lett. 259 (1999) 62-64
17. Banik R.K., Kozaki Y., Sato J., Gera L., and Mizumura K. B2 receptor-mediated enhanced bradykinin sensitivity of rat cutaneous C-fiber nociceptors during persistent inflammation. J. Neurophysiol. 86 (2001) 2727-2735
18. Carlton S.M., and Coggeshall R.E. Inflammation-induced up-regulation of neurokinin 1 receptors in rat glabrous skin. Neurosci. Lett. 326 (2002) 29-32
19. von Banchet G.S., Petrow P.K., Bräuer R., and Schaible H.G. Monoarticular antigen-induced arthritis leads to pronounced bilateral upregulation of the expression of neurokinin 1 and bradykinin 2 receptors in dorsal root ganglion neurons of rats. Arthritis Res. 2 (2000) 424-427
20. Lewin G.R., Rueff A., and Mendell L.M. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur. J. Neurosci. 6 (1994) 1903-1912
21. Segond V.B., Scholze A., and Schaible H.G. Prostaglandin E2 increases the expression of the neurokinin1 receptor in adult sensory neurones in culture: a novel role of prostaglandins. Br. J. Pharmacol. 139 (2003) 672-680
22. Liu C.N., Michaelis M., Amir R., and Devor M. Spinal nerve injury enhances subthreshold membrane potential oscillations in DRG neurons: relation to neuropathic pain. J. Neurophysiol. 84 (2000) 205-215
23. Wu G., Ringkamp M., Hartke T.V., Murinson B.B., Campbell J.N., Griffin J.W., and Meyer R.A. Early onset of spontaneous activity in uninjured C-fiber nociceptors after injury to neighboring nerve fibers. J. Neurosci. 21 (2001) (art-RC137)
24. Cummins T.R., Dib-Hajj S.D., Black J.A., and Waxman S.G. Sodium channels and the molecular pathophysiology of pain. Prog. Brain Res. 129 3-19 (2000) 3-19
25. Schaible H.G., and Richter F. Pathophysiology of pain. Langenbeck's Arch. Surg. 389 (2004) 237-243
26. Jänig W., Levine J.D., and Michaelis M. Interactions of sympathetic and primary afferent neurons following nerve injury and tissue trauma. Prog. Brain Res. 113 (1996) 161-184
27. Treede R.D., Kenshalo D.R., Gracely R.H., and Jones A. The cortical representation of pain. Pain 79 (1999) 105-111
28. Basbaum A.I., and Jessell T.M. The perception of pain. In: Kandell E.R., and Jessel T.M. (Eds). Principles of Neural Science (1999), Mc Graw-Hill, New York 472-491
29. Woolf C.J. Evidence for a central component of post-injury pain hypersensitivity. Nature 306 (1983) 686-688
30. Schaible H.G., Del Rosso A., and Matucci-Cerinic M. Neurogenic aspects of inflammation. Rheum. Dis. Clin. North Am. 31 (2005) 77-101
31. Sandkuhler J., and Liu X. Induction of long-term potentiation at spinal synapses by noxious stimulation or nerve injury. Eur. J Neurosci. 10 (1998) 2476-2480
32. Gautron M., and Guilbaud G. Somatic responses of ventrobasal thalamic neurones in polyarthritic rats. Brain Res. 237 (1982) 459-471
33. Lamour Y., Guilbaud G., and Willer J.C. Altered properties and laminar distribution of neuronal responses to peripheral stimulation in the SmI cortex of the arthritic rat. Brain Res. 273 (1983) 183-187
34. Vanegas H., and Schaible H.G. Descending control of persistent pain: inhibitory or facilitatory?. Brain Res. Rev. 46 (2004) 295-309
35. Danziger N., Weil-Fugazza J., Le Bars D., and Bouhassira D. Stage-dependent changes in the modulation of spinal nociceptive neuronal activity during the course of inflammation. Eur. J. Neurosci. 13 (2001) 230-240
36. Fundytus M.E. Glutamate receptors and nociception: implications for the drug treatment of pain. CNS Drugs 15 (2001) 29-58
37. Schaible H.G., Jarrott B., Hope P.J., and Duggan A.W. Release of immunoreactive substance P in the spinal cord during development of acute arthritis in the knee joint of the cat: a study with antibody microprobes. Brain Res. 529 (1990) 214-223
38. Schaible H.G., Freudenberger U., Neugebauer V., and Stiller R.U. Intraspinal release of immunoreactive calcitonin gene-related peptide during development of inflammation in the joint in vivo-a study with antibody microprobes in cat and rat. Neuroscience 62 (1994) 1293-1305
39. Hope P.J., Jarrott B., Schaible H.G., Clarke R.W., and Duggan A.W. Release and spread of immunoreactive neurokinin A in the cat spinal cord in a model of acute arthritis. Brain Res. 533 (1990) 292-299
40. Neugebauer V., Weiretter F., and Schaible H.G. Involvement of substance P and neurokinin-1 receptors in the hyperexcitability of dorsal horn neurons during development of acute arthritis in rat's knee joint. J. Neurophysiol. 73 (1995) 1574-1583
41. Neugebauer V., Rümenapp P., and Schaible H.G. Calcitonin gene-related peptide is involved in the spinal processing of mechanosensory input from the rat's knee joint and in the generation and maintenance of hyperexcitability of dorsal horn-neurons during development of acute inflammation. Neuroscience 71 (1996) 1095-1109
42. Neugebauer V., Rümenapp P., and Schaible H.G. The role of spinal neurokinin-2 receptors in the processing of nociceptive information from the joint and in the generation and maintenance of inflammation-evoked hyperexcitability of dorsal horn neurons in the rat. Eur. J. Neurosci. 8 (1996) 249-260
43. Ebersberger A., Charbel I.P., Vanegas H., and Schaible H.G. Differential effects of calcitonin gene-related peptide and calcitonin gene-related peptide 8-37 upon responses to N-methyl-D-aspartate or (R, S)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate in spinal nociceptive neurons with knee joint input in the rat. Neuroscience 99 (2000) 171-178
44. Urban L., Thompson S.W., and Dray A. Modulation of spinal excitability: co-operation between neurokinin and excitatory amino acid neurotransmitters. Trends Neurosci. 17 (1994) 432-438
45. Sommer C. Painful neuropathies. Curr. Opin. Neurol. 16 (2003) 623-628
46. Sommer C., and Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci. Lett. 361 (2004) 184-187
47. Watkins L.R., Milligan E.D., and Maier S.F. Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Adv. Exp. Med. Biol. 521 1-21 (2003) 1-21
48. Wieseler-Frank J., Maier S.F., and Watkins L.R. Glial activation and pathological pain. Neurochem. Int. 45 (2004) 389-395
49. Johnston I.N., Milligan E.D., Wieseler-Frank J., Frank M.G., Zapata V., Campisi J., Langer S., Martin D., Green P., Fleshner M., Leinwand L., Maier S.F., and Watkins L.R. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J. Neurosci. 24 (2004) 9353-9365
50. Russo C.M., and Brose W.G. Chronic pain. Annu. Rev. Med. 49 123-33 (1998) 123-133
51. Chapman C.R., and Gavrin J. Suffering: the contributions of persistent pain. Lancet 353 (1999) 2233-2237
52. Kendall N.A. Psychosocial approaches to the prevention of chronic pain: the low back paradigm, Baillieres Best. Pract. Res. Clin. Rheumatol. 13 (1999) 545-554
53. Flor H. Painful memories. Can we train chronic pain patients to 'forget' their pain?. EMBO Rep. 3 (2002) 288-291
54. Flor H., Knost B., and Birbaumer N. The role of operant conditioning in chronic pain: an experimental investigation. Pain 95 (2002) 111-118
55. Thieme K., Gromnica-Ihle E., and Flor H. Operant behavioral treatment of fibromyalgia: a controlled study. Arthritis Rheum. 49 (2003) 314-320
56. Schaible H.G., and Schmidt R.F. Excitation and sensitization of fine articular afferents from cat's knee joint by prostaglandin E2. J. Physiol. 403 91-104 (1988) 91-104
57. Malmberg A.B., and Yaksh T.L. Cyclooxygenase inhibition and the spinal release of prostaglandin E2 and amino acids evoked by paw formalin injection: a microdialysis study in unanesthetized rats. J. Neurosci. 15 (1995) 2768-2776
58. Geisslinger G., Muth-Selbach U., Coste O., Vetter G., Schrodter A., Schaible H.G., Brune K., and Tegeder I. Inhibition of noxious stimulus-induced spinal prostaglandin E2 release by flurbiprofen enantiomers: a microdialysis study. J. Neurochem. 74 (2000) 2094-2100
59. Woolf C.J., and King A.E. Dynamic alterations in the cutaneous mechanoreceptive fields of dorsal horn neurons in the rat spinal cord. J. Neurosci. 10 (1990) 2717-2726
60. Nicol G.D., Klingberg D.K., and Vasko M.R. Prostaglandin E2 increases calcium conductance and stimulates release of substance P in avian sensory neurons. J. Neurosci. 12 (1992) 1917-1927
61. Hingtgen C.M., Waite K.J., and Vasko M.R. Prostaglandins facilitate peptide release from rat sensory neurons by activating the adenosine 3′,5′-cyclic monophosphate transduction cascade. J. Neurosci. 15 (1995) 5411-5419
62. Harvey R.J., Depner U.B., Wassle H., Ahmadi S., Heindl C., Reinold H., Smart T.G., Harvey K., Schutz B., Abo-Salem O.M., Zimmer A., Poisbeau P., Welzl H., Wolfer D.P., Betz H., Zeilhofer H.U., and Muller U. GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science 304 (2004) 884-887
63. Ahmadi S., Lippross S., Neuhuber W.L., and Zeilhofer H.U. PGE(2) selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons. Nat. Neurosci. 5 (2002) 34-40
64. Baba H., Kohno T., Moore K.A., and Woolf C.J. Direct activation of rat spinal dorsal horn neurons by prostaglandin E2. J. Neurosci. 21 (2001) 1750-1756
65. Nicol G.D., Vasko M.R., and Evans A.R. Prostaglandins suppress an outward potassium current in embryonic rat sensory neurons. J. Neurophysiol. 77 (1997) 167-176
66. Evans A.R., Vasko M.R., and Nicol G.D. The cAMP transduction cascade mediates the PGE2-induced inhibition of potassium currents in rat sensory neurones. J. Physiol. 516 (1999) 163-178
67. Beiche F., Klein T., Nusing R., Neuhuber W., and Goppelt-Struebe M. Localization of cyclooxygenase-2 and prostaglandin E2 receptor EP3 in the rat lumbar spinal cord. J. Neuroimmunol. 89 (1998) 26-34
68. Minami T., Nakano H., Kobayashi T., Sugimoto Y., Ushikubi F., Ichikawa A., Narumiya S., and Ito S. Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice. Br. J. Pharmacol. 133 (2001) 438-444
69. Sarkar S., Hobson A.R., Hughes A., Growcott J., Woolf C.J., Thompson D.G., and Aziz Q. The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology 124 (2003) 18-25
70. Eguchi N., Minami T., Shirafuji N., Kanaoka Y., Tanaka T., Nagata A., Yoshida N., Urade Y., Ito S., and Hayaishi O. Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 726-730
71. Doi Y., Minami T., Nishizawa M., Mabuchi T., Mori H., and Ito S. Central nociceptive role of prostacyclin (IP) receptor induced by peripheral inflammation. NeuroReport 13 (2002) 93-96
72. Murata T., Ushikubi F., Matsuoka T., Hirata M., Yamasaki A., Sugimoto Y., Ichikawa A., Aze Y., Tanaka T., Yoshida N., Ueno A., Oh-ishi S., and Narumiya S. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388 (1997) 678-682
73. Muratani T., Nishizawa M., Matsumura S., Mabuchi T., Abe K., Shimamoto K., Minami T., and Ito S. Functional characterization of prostaglandin F2alpha receptor in the spinal cord for tactile pain (allodynia). J. Neurochem. 86 (2003) 374-382
74. Bär K.J., Natura G., Telleria-Diaz A., Teschner P., Vogel R., Vasquez E., Schaible H.G., and Ebersberger A. Changes in the effect of spinal prostaglandin E2 during inflammation: prostaglandin E (EP1-EP4) receptors in spinal nociceptive processing of input from the normal or inflamed knee joint. J. Neurosci. 24 (2004) 642-651
75. Maggi Jr. L.B., Sadeghi H., Weigand C., Scarim A.L., Heitmeier M.R., and Corbett J.A. Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and-independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes 49 (2000) 346-355
76. Tsubouchi Y., Kawahito Y., Kohno M., Inoue K., Hla T., and Sano H. Feedback control of the arachidonate cascade in rheumatoid synoviocytes by 15-deoxy-Delta(12,14)-prostaglandin J2. Biochem. Biophys. Res. Commun. 283 (2001) 750-755
77. Boyault S., Simonin M.A., Bianchi A., Compe E., Liagre B., Mainard D., Becuwe P., Dauca M., Netter P., Terlain B., and Bordji K. 15-Deoxy-delta12,14-PGJ2, but not troglitazone, modulates IL-1beta effects in human chondrocytes by inhibiting NF-kappaB and AP-1 activation pathways. FEBS Lett. 501 (2001) 24-30
78. Straus D.S., Pascual G., Li M., Welch J.S., Ricote M., Hsiang C.H., Sengchanthalangsy L.L., Ghosh G., and Glass C.K. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4844-4849
79. Trebino C.E., Stock J.L., Gibbons C.P., Naiman B.M., Wachtmann T.S., Umland J.P., Pandher K., Lapointe J.M., Saha S., Roach M.L., Carter D., Thomas N.A., Durtschi B.A., McNeish J.D., Hambor J.E., Jakobsson P.J., Carty T.J., Perez J.R., and Audoly L.P. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9044-9049
80. Mabuchi T., Kojima H., Abe T., Takagi K., Sakurai M., Ohmiya Y., Uematsu S., Akira S., Watanabe K., and Ito S. Membrane-associated prostaglandin E synthase-1 is required for neuropathic pain. NeuroReport 15 (2004) 1395-1398
81. Kamei D., Yamakawa K., Takegoshi Y., Mikami-Nakanishi M., Nakatani Y., Oh-ishi S., Yasui H., Azuma Y., Hirasawa N., Ohuchi K., Kawaguchi H., Ishikawa Y., Ishii T., Uematsu S., Akira S., Murakami M., and Kudo I. Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin e synthase-1. J. Biol. Chem. 279 (2004) 33684-33695
82. Meller S.T., Cummings C.P., Traub R.J., and Gebhart G.F. The role of nitric oxide in the development and maintenance of the hyperalgesia produced by intraplantar injection of carrageenan in the rat. Neuroscience 60 (1994) 367-374
83. Meller S.T., and Gebhart G.F. Nitric oxide (NO) and nociceptive processing in the spinal cord. Pain 52 (1993) 127-136
84. Whittle B.J. Cyclooxygenase and nitric oxide systems in the gut as therapeutic targets for safer anti-inflammatory drugs. Curr. Opin. Pharmacol. 4 (2004) 538-545
85. Davies N.M., Roseth A.G., Appleyard C.B., McKnight W., Del Soldato P., Calignano A., Cirino G., and Wallace J.L. NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment. Pharmacol. Ther. 11 (1997) 69-79
86. Cicala C., Ianaro A., Fiorucci S., Calignano A., Bucci M., Gerli R., Santucci L., Wallace J.L., and Cirino G. NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis. Br. J. Pharmacol. 130 (2000) 1399-1405
87. al Swayeh O.A., Futter L.E., Clifford R.H., and Moore P.K. Nitroparacetamol exhibits anti-inflammatory and anti-nociceptive activity. Br. J. Pharmacol. 130 (2000) 1453-1456
88. al Swayeh O.A., Clifford R.H., Del Soldato P., and Moore P.K. A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin. Br. J. Pharmacol. 129 (2000) 343-350
89. Romero-Sandoval E.A., Mazario J., Howat D., and Herrero J.F. NCX-701 (nitroparacetamol) is an effective antinociceptive agent in rat withdrawal reflexes and wind-up. Br. J. Pharmacol. 135 (2002) 1556-1562
90. Keeble J.E., and Moore P.K. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br. J. Pharmacol. 137 (2002) 295-310
91. Zacharowski P., Zacharowski K., Donnellan C., Johnston A., Vojnovic I., Forte P., Del Soldato P., Benjamin N., and O'Byrne S. The effects and metabolic fate of nitroflurbiprofen in healthy volunteers. Clin. Pharmacol. Ther. 76 (2004) 350-358
92. Fiorucci S., Distrutti E., de Lima O.M., Romano M., Mencarelli A., Barbanti M., Palazzini E., Morelli A., and Wallace J.L. Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lip ooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J. 17 (2003) 1171-1173
93. Gay R.E., Neidhart M., Pataky F., Tries S., Laufer S., and Gay S. Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis. J. Rheumatol. 28 (2001) 2060-2065
94. Jovanovic D.V., Fernandes J.C., Martel-Pelletier J., Jolicoeur F.C., Reboul P., Laufer S., Tries S., and Pelletier J.P. In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1beta synthesis. Arthritis Rheum. 44 (2001) 2320-2330
95. Lajeunesse D., Martel-Pelletier J., Fernandes J.C., Laufer S., and Pelletier J.P. Treatment with licofelone prevents abnormal subchondral bone cell metabolism in experimental dog osteoarthritis. Ann. Rheum. Dis. 63 (2004) 78-83
96. Pelletier J.P., Boileau C., Brunet J., Boily M., Lajeunesse D., Reboul P., Laufer S., and Martel-Pelletier J. The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone 34 (2004) 527-538
97. Bias P., Buchner A., Klesser B., and Laufer S. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial. Am. J. Gastroenterol. 99 (2004) 611-618
98. Kobal G. Pain-related electrical potentials of the human nasal mucosa elicited by chemical stimulation. Pain 22 (1985) 151-163
99. Stein C., Schäfer M., and Hassan A.H. Peripheral opioid receptors. Ann. Med. 27 (1995) 219-221
100. Stein C., Millan M.J., Shippenberg T.S., and Herz A. Peripheral effect of fentanyl upon nociception in inflamed tissue of the rat. Neurosci. Lett. 84 (1988) 225-228
101. Stein C., Millan M.J., Shippenberg T.S., Peter K., and Herz A. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. J. Pharmacol. Exp. Ther. 248 (1989) 1269-1275
102. Parsons C.G., Czlonkowski A., Stein C., and Herz A. Peripheral opioid receptors mediating antinociception in inflammation. Activation by endogenous opioids and role of the pituitary-adrenal axis. Pain 41 (1990) 81-93
103. Levine J.D., and Taiwo Y.O. Involvement of the mu-opiate receptor in peripheral analgesia. Neuroscience 32 (1989) 571-575
104. Kolesnikov Y.A., Jain S., Wilson R., and Pasternak G.W. Peripheral morphine analgesia: synergy with central sites and a target of morphine tolerance. J. Pharmacol. Exp. Ther. 279 (1996) 502-506
105. Perrot S., Guilbaud G., and Kayser V. Effects of intraplantar morphine on paw edema and pain-related behaviour in a rat model of repeated acute inflammation. Pain 83 (1999) 249-257
106. Hassan A.H., Ableitner A., Stein C., and Herz A. Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue. Neuroscience 55 (1993) 185-195
107. Schäfer M., Imai Y., Uhl G.R., and Stein C. Inflammation enhances peripheral mu-opioid receptor-mediated analgesia, but not mu-opioid receptor transcription in dorsal root ganglia. Eur. J. Pharmacol. 279 (1995) 165-169
108. Stein C., Pfluger M., Yassouridis A., Hoelzl J., Lehrberger K., Welte C., and Hassan A.H. No tolerance to peripheral morphine analgesia in presence of opioid expression in inflamed synovia. J. Clin. Invest. 98 (1996) 793-799
109. Mousa S.A., Zhang Q., Sitte N., Ji R., and Stein C. Beta-Endorphin-containing memory-cells and mu-opioid receptors undergo transport to peripheral inflamed tissue. J. Neuroimmunol. 115 (2001) 71-78
110. Binder W., Mousa S.A., Sitte N., Kaiser M., Stein C., and Schäfer M. Sympathetic activation triggers endogenous opioid release and analgesia within peripheral inflamed tissue. Eur. J. Neurosci. 20 (2004) 92-100
111. Machelska H., Cabot P.J., Mousa S.A., Zhang Q., and Stein C. Pain control in inflammation governed by selectins. Nat. Med. 4 (1998) 1425-1428
112. Schäfer M., Mousa S.A., Zhang Q., Carter L., and Stein C. Expression of corticotropin-releasing factor in inflamed tissue is required for intrinsic peripheral opioid analgesia. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 6096-6100
113. Schäfer M., Mousa S.A., and Stein C. Corticotropin-releasing factor in antinociception and inflammation. Eur. J. Pharmacol. 323 (1997) 1-10
114. Rittner H.L., Brack A., Machelska H., Mousa S.A., Bauer M., Schäfer M., and Stein C. Opioid peptide-expressing leukocytes: identification, recruitment, and simultaneously increasing inhibition of inflammatory pain. Anesthesiology 95 (2001) 500-508
115. Machelska H., Mousa S.A., Brack A., Schopohl J.K., Rittner H.L., Schäfer M., and Stein C. Opioid control of inflammatory pain regulated by intercellular adhesion molecule-1. J. Neurosci. 22 (2002) 5588-5596
116. Stein C., Comisel K., Haimerl E., Yassouridis A., Lehrberger K., Herz A., and Peter K. Analgesic effect of intraarticular morphine after arthroscopic knee surgery. N. Engl. J. Med. 325 (1991) 1123-1126
117. Whitford A., Healy M., Joshi G.P., McCarroll S.M., and O'Brien T.M. The effect of tourniquet release time on the analgesic efficacy of intraarticular morphine after arthroscopic knee surgery. Anesth. Analg. 84 (1997) 791-793
118. Joshi G.P., McCarroll S.M., Brady O.H., Hurson B.J., and Walsh G. Intra-articular morphine for pain relief after anterior cruciate ligament repair. Br. J. Anaesth. 70 (1993) 87-88
119. Joshi G.P., McCarroll S.M., O'Brien T.M., and Lenane P. Intraarticular analgesia following knee arthroscopy. Anesth. Analg. 76 (1993) 333-336
120. McSwiney M.M., Joshi G.P., Kenny P., and McCarroll S.M. Analgesia following arthroscopic knee surgery. A controlled study of intra-articular morphine, bupivacaine or both combined. Anaesth. Intensive Care 21 (1993) 201-203
121. Likar R., Sittl R., Gragger K., Pipam W., Blatnig H., Breschan C., Schalk H.V., Stein C., and Schäfer M. Peripheral morphine analgesia in dental surgery. Pain 76 (1998) 145-150
122. Cerchietti L.C., Navigante A.H., Bonomi M.R., Zaderajko M.A., Menendez P.R., Pogany C.E., and Roth B.M. Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma. Cancer 95 (2002) 2230-2236
123. Cerchietti L.C., Navigante A.H., Korte M.W., Cohen A.M., Quiroga P.N., Villaamil E.C., Bonomi M.R., and Roth B.M. Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study. Pain 105 (2003) 265-273
124. Tegeder I., Meier S., Burian M., Schmidt H., Geisslinger G., and Lotsch J. Peripheral opioid analgesia in experimental human pain models. Brain 126 (2003) 1092-1102
125. Furst S., Riba P., Friedmann T., Timar J., Al Khrasani M., Obara I., Makuch W., Spetea M., Schutz J., Przewlocki R., Przewlocka B., and Schmidhammer H. Peripheral versus central antinociceptive actions of 6-amino acid-substituted derivatives of 14-O-methyloxymorphone in acute and inflammatory pain in the rat. J. Pharmacol. Exp. Ther. 312 (2005) 609-618
126. Romero A., Planas E., Poveda R., Sanchez S., Pol O., and Puig M.M. Anti-exudative effects of opioid receptor agonists in a rat model of carrageenan-induced acute inflammation of the paw. Eur. J. Pharmacol. 511 (2005) 207-217
127. Janson W., and Stein C. Peripheral opioid analgesia. Curr. Pharm. Biotechnol. 4 (2003) 270-274
128. Tham S.M., Angus J.A., Tudor E.M., and Wright C.E. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice. Br. J. Pharmacol. 144 (2005) 875-884
129. Jaggar S.I., Hasnie F.S., Sellaturay S., and Rice A.S. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76 (1998) 189-199
130. Gühring H., Schuster J., Hamza M., Ates M., Kotalla C.E., and Brune K. HU-210 shows higher efficacy and potency than morphine after intrathecal administration in the mouse formalin test. Eur. J. Pharmacol. 429 (2001) 127-134
131. Lim G., Sung B., Ji R.R., and Mao J. Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 105 (2003) 275-283
132. Scott D.A., Wright C.E., and Angus J.A. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 109 (2004) 124-131
133. Costa B., Colleoni M., Conti S., Trovato A.E., Bianchi M., Sotgiu M.L., and Giagnoni G. Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. Br. J. Pharmacol. 141 (2004) 4-8
134. Cox M.L., and Welch S.P. The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat. Eur. J. Pharmacol. 493 (2004) 65-74
135. Sumariwalla P.F., Gallily R., Tchilibon S., Fride E., Mechoulam R., and Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum. 50 (2004) 985-998
136. Gauldie S.D., McQueen D.S., Pertwee R., and Chessell I.P. Anandamide activates peripheral nociceptors in normal and arthritic rat knee joints. Br. J. Pharmacol. 132 (2001) 617-621
137. Malfait A.M., Gallily R., Sumariwalla P.F., Malik A.S., Andreakos E., Mechoulam R., and Feldmann M. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 9561-9566
138. Mbvundula E.C., Bunning R.A., and Rainsford K.D. Effects of cannabinoids on nitric oxide production by chondrocytes and proteoglycan degradation in cartilage. Biochem. Pharmacol. 69 (2005) 635-640
139. Farquhar-Smith W.P., Egertova M., Bradbury E.J., McMahon S.B., Rice A.S., and Elphick M.R. Cannabinoid CB(1) receptor expression in rat spinal cord. Mol. Cell. Neurosci. 15 (2000) 510-521
140. Richardson J.D., Kilo S., and Hargreaves K.M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75 (1998) 111-119
141. Elmes S.J., Jhaveri M.D., Smart D., Kendall D.A., and Chapman V. Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur. J. Neurosci. 20 (2004) 2311-2320
142. Ibrahim M.M., Porreca F., Lai J., Albrecht P.J., Rice F.L., Khodorova A., Davar G., Makriyannis A., Vanderah T.W., Mata H.P., and Malan Jr. T.P. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3093-3098
143. Nackley A.G., Zvonok A.M., Makriyannis A., and Hohmann A.G. Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J. Neurophysiol. 92 (2004) 3562-3574
144. Svendsen K.B., Jensen T.S., and Bach F.W. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 329 (2004) 253
145. Auphan N., DiDonato J.A., Rosette C., Helmberg A., and Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270 (1995) 286-290
146. Marok R., Winyard P.G., Coumbe A., Kus M.L., Gaffney K., Blades S., Mapp P.I., Morris C.J., Blake D.R., Kaltschmidt C., and Baeuerle P.A. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum. 39 (1996) 583-591
147. Tak P.P., Gerlag D.M., Aupperle K.R., van de Geest D.A., Overbeek M., Bennett B.L., Boyle D.L., Manning A.M., and Firestein G.S. Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum. 44 (2001) 1897-1907
148. Tegeder I., Niederberger E., Israr E., Gühring H., Brune K., Euchenhofer C., Grosch S., and Geisslinger G. Inhibition of NF-kappaB and AP-1 activation by R-and S-flurbiprofen. FASEB J. 15 (2001) 595-597
149. Neurath M.F., Pettersson S., Meyer zum Büschenfelde K.H., and Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat. Med. 2 (1996) 998-1004
150. Kopp E., and Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265 (1994) 956-959
151. Dai S., Hirayama T., Abbas S., and Abu-Amer Y. The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J. Biol. Chem. 279 (2004) 37219-37222
152. Clohisy J.C., Roy B.C., Biondo C., Frazier E., Willis D., Teitelbaum S.L., and Abu-Amer Y. Direct inhibition of NF-kappa B blocks bone erosion associated with inflammatory arthritis. J. Immunol. 171 (2003) 5547-5553
153. Jimi E., Aoki K., Saito H., D'Acquisto F., May M.J., Nakamura I., Sudo T., Kojima T., Okamoto F., Fukushima H., Okabe K., Ohya K., and Ghosh S. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat. Med. 10 (2004) 617-624
154. Iotsova V., Caamano J., Loy J., Yang Y., Lewin A., and Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat. Med. 3 (1997) 1285-1289
155. DiDonato J., Mercurio F., Rosette C., Wu-Li J., Suyang H., Ghosh S., and Karin M. Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol. Cell. Biol. 16 (1996) 1295-1304
156. Gao Y., Lecker S., Post M.J., Hietaranta A.J., Li J., Volk R., Li M., Sato K., Saluja A.K., Steer M.L., Goldberg A.L., and Simons M. Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J. Clin. Invest. 106 (2000) 439-448
157. Lin Y.Z., Yao S.Y., Veach R.A., Torgerson T.R., and Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J. Biol. Chem. 270 (1995) 14255-14258
158. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18 (1999) 6853-6866
159. Zandi E., Chen Y., and Karin M. Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate. Science 281 (1998) 1360-1363
160. Mercurio F., Zhu H., Murray B.W., Shevchenko A., Bennett B.L., Li J., Young D.B., Barbosa M., Mann M., Manning A., and Rao A. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 278 (1997) 860-866
161. DiDonato J.A., Hayakawa M., Rothwarf D.M., Zandi E., and Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 388 (1997) 548-554
162. Rothwarf D.M., Zandi E., Natoli G., and Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 395 (1998) 297-300
163. Delhase M., Hayakawa M., Chen Y., and Karin M. Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science 284 (1999) 309-313
164. Jeon K.I., Jeong J.Y., and Jue D.M. Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase. J. Immunol. 164 (2000) 5981-5989
165. Yang J.P., Merin J.P., Nakano T., Kato T., Kitade Y., and Okamoto T. Inhibition of the DNA-binding activity of NF-kappa B by gold compounds in vitro. FEBS Lett. 361 (1995) 89-96
166. Ray A., and Prefontaine K.E. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 752-756
167. Scheinman R.I., Cogswell P.C., Lofquist A.K., and Baldwin Jr. A.S. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270 (1995) 283-286
168. Yin M.J., Yamamoto Y., and Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396 (1998) 77-80
169. Tegeder I., Niederberger E., Schmidt R., Kunz S., Gühring H., Ritzeler O., Michaelis M., and Geisslinger G. Specific Inhibition of IkappaB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats. J. Neurosci. 24 (2004) 1637-1645
170. Podolin P.L., Callahan J.F., Bolognese B.J., Li Y.H., Carlson K., Davis T.G., Mellor G.W., Evans C., and Roshak A.K. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation. J. Pharmacol. Exp. Ther. 312 (2005) 373-381
171. Takada Y., Kobayashi Y., and Aggarwal B.B. Evodiamine abolishes constitutive and inducible NF-{kappa}B activation by inhibiting I{kappa}B{alpha} kinase activation, thereby suppressing NF-{kappa}B-regulated antiapoptotic and metastatic gene expression, Up-regulating apoptosis, and inhibiting invasion. J. Biol. Chem. 280 (2005) 17203-17212
172. Park H.J., Lee S.H., Son D.J., Oh K.W., Kim K.H., Song H.S., Kim G.J., Oh G.T., Yoon d.Y., and Hong J.T. Antiarthritic effect of bee venom: inhibition of inflammation mediator generation by suppression of NF-kappaB through interaction with the p50 subunit. Arthritis Rheum. 50 (2004) 3504-3515
173. Urushibara M., Takayanagi H., Koga T., Kim S., Isobe M., Morishita Y., Nakagawa T., Loeffler M., Kodama T., Kurosawa H., and Taniguchi T. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum. 50 (2004) 794-804
174. Quinn J.M., Horwood N.J., Elliott J., Gillespie M.T., and Martin T.J. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. J. Bone Miner. Res. 15 (2000) 1459-1466
175. Udagawa N., Takahashi N., Jimi E., Matsuzaki K., Tsurukai T., Itoh K., Nakagawa N., Yasuda H., Goto M., Tsuda E., Higashio K., Gillespie M.T., Martin T.J., and Suda T. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. Bone 25 (1999) 517-523
176. Klareskog L., van der H.D., de Jager J.P., Gough A., Kalden J., Malaise M., Martin M.E., Pavelka K., Sany J., Settas L., Wajdula J., Pedersen R., Fatenejad S., and Sanda M. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
177. van de Putte L.B., Rau R., Breedveld F.C., Kalden J.R., Malaise M.G., van Riel P.L., Schattenkirchner M., Emery P., Burmester G.R., Zeidler H., Moutsopoulos H.M., Beck K., and Kupper H. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann. Rheum. Dis. 62 (2003) 1168-1177
178. Hochberg M.C., Tracy J.K., Hawkins-Holt M., and Flores R.H. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 62 Suppl 2:ii13-6 (2003) ii13-ii16
179. Samad T.A., Moore K.A., Sapirstein A., Billet S., Allchorne A., Poole S., Bonventre J.V., and Woolf C.J. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410 (2001) 471-475
180. Ledeboer A., Sloane E.M., Milligan E.D., Frank M.G., Mahony J.H., Maier S.F., and Watkins L.R. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 115 (2005) 71-83
181. Hoheisel U., Unger T., and Mense S. Excitatory and modulatory effects of inflammatory cytokines and neurotrophins on mechanosensitive group IV muscle afferents in the rat. Pain 114 (2005) 168-176
182. Schäfers M., Svensson C.I., Sommer C., and Sorkin L.S. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J. Neurosci. 23 (2003) 2517-2521
183. Steen K.H., Steen A.E., and Reeh P.W. A dominant role of acid pH in inflammatory excitation and sensitization of nociceptors in rat skin, in vitro. J. Neurosci. 15 (1995) 3982-3989
184. Waldmann R., Champigny G., Bassilana F., Heurteaux C., and Lazdunski M. A proton-gated cation channel involved in acid-sensing. Nature 386 (1997) 173-177
185. 2+ permeability of the sustained proton-induced cation current in adult rat dorsal root ganglion neurons. J. Neurophysiol. 76 (1996) 2834-2840
186. Kress M., and Zeilhofer H.U. Capsaicin, protons and heat: new excitement about nociceptors. Trends Pharmacol. Sci. 20 (1999) 112-118
187. Sugiura T., Dang K., Lamb K., Bielefeldt K., and Gebhart G.F. Acid-sensing properties in rat gastric sensory neurons from normal and ulcerated stomach. J. Neurosci. 25 (2005) 2617-2627
188. Sluka K.A., Price M.P., Breese N.M., Stucky C.L., Wemmie J.A., and Welsh M.J. Chronic hyperalgesia induced by repeated acid injections in muscle is abolished by the loss of ASIC3, but not ASIC1. Pain 106 (2003) 229-239
189. Wemmie J.A., Chen J., Askwith C.C., Hruska-Hageman A.M., Price M.P., Nolan B.C., Yoder P.G., Lamani E., Hoshi T., Freeman Jr. J.H., and Welsh M.J. The acid-activated ion channel ASIC contributes to synaptic plasticity, learning, and memory. Neuron 34 (2002) 463-477
190. Chen C.C., Zimmer A., Sun W.H., Hall J., Brownstein M.J., and Zimmer A. A role for ASIC3 in the modulation of high-intensity pain stimuli. Proc. Natl. Acad. Sci.U. S. A. 99 (2002) 8992-8997
191. Sutherland S.P., Benson C.J., Adelman J.P., and McCleskey E.W. Acid-sensing ion channel 3 matches the acid-gated current in cardiac ischemia-sensing neurons. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 711-716
192. Immke D.C., and McCleskey E.W. Lactate enhances the acid-sensing Na+channel on ischemia-sensing neurons. Nat. Neurosci. 4 (2001) 869-870
193. Baron A., Waldmann R., and Lazdunski M. ASIC-like, proton-activated currents in rat hippocampal neurons. J. Physiol. 539 (2002) 485-494
194. Wu L.J., Duan B., Mei Y.D., Gao J., Chen J.G., Zhuo M., Xu L., Wu M., and Xu T.L. Characterization of acid-sensing ion channels in dorsal horn neurons of rat spinal cord. J. Biol. Chem. 279 (2004) 43716-43724
195. Chen C.C., England S., Akopian A.N., and Wood J.N. A sensory neuron-specific, proton-gated ion channel. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 10240-10245
196. Mamet J., Baron A., Lazdunski M., and Voilley N. Proinflammatory mediators, stimulators of sensory neuron excitability via the expression of acid-sensing ion channels. J. Neurosci. 22 (2002) 10662-10670
197. Deval E., Baron A., Lingueglia E., Mazarguil H., Zajac J.M., and Lazdunski M. Effects of neuropeptide SF and related peptides on acid sensing ion channel 3 and sensory neuron excitability. Neuropharmacology 44 (2003) 662-671
198. Yermolaieva O., Leonard A.S., Schnizler M.K., Abboud F.M., and Welsh M.J. Extracellular acidosis increases neuronal cell calcium by activating acid-sensing ion channel 1a. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 6752-6757
199. Jones N.G., Slater R., Cadiou H., McNaughton P., and McMahon S.B. Acid-induced pain and its modulation in humans. J. Neurosci. 24 (2004) 10974-10979
200. Steen K.H., Reeh P.W., and Kreysel H.W. Dose-dependent competitive block by topical acetylsalicylic and salicylic acid of low pH-induced cutaneous pain. Pain 64 (1996) 71-82
201. Voilley N., de Weille J., Mamet J., and Lazdunski M. Nonsteroid anti-inflammatory drugs inhibit both the activity and the inflammation-induced expression of acid-sensing ion channels in nociceptors. J. Neurosci. 21 (2001) 8026-8033
202. Escoubas P., Bernard C., Lambeau G., Lazdunski M., and Darbon H. Recombinant production and solution structure of PcTx1, the specific peptide inhibitor of ASIC1a proton-gated cation channels. Protein Sci. 12 (2003) 1332-1343
203. Diochot S., Baron A., Rash L.D., Deval E., Escoubas P., Scarzello S., Salinas M., and Lazdunski M. A new sea anemone peptide, APETx2, inhibits ASIC3, a major acid-sensitive channel in sensory neurons. EMBO J. 23 (2004) 1516-1525
204. Agarwal N., Offermanns S., and Kuner R. Conditional gene deletion in primary nociceptive neurons of trigeminal ganglia and dorsal root ganglia. Genesis 38 (2004) 122-129
205. Stirling L.C., Forlani G., Baker M.D., Wood J.N., Matthews E.A., Dickenson A.H., and Nassar M.A. Nociceptor-specific gene deletion using heterozygous NaV1.8-Cre recombinase mice. Pain 113 (2005) 27-36
206. Nassar M.A., Stirling L.C., Forlani G., Baker M.D., Matthews E.A., Dickenson A.H., and Wood J.N. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 12706-12711
207. + currents in mouse colonic dorsal root ganglia neurons and their role in colitis-induced hyperexcitability. Am. J. Physiol.: Gasterointest. Liver Physiol. 287 (2004) G845-G855
208. Caterina M.J., Leffler A., Malmberg A.B., Martin W.J., Trafton J., Petersen-Zeitz K.R., Koltzenburg M., Basbaum A.I., and Julius D. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288 (2000) 306-313
209. Geppetti P., and Trevisani M. Activation and sensitisation of the vanilloid receptor: role in gastrointestinal inflammation and function. Br. J. Pharmacol. 141 (2004) 1313-1320
210. Gavva N.R., Klionsky L., Qu Y., Shi L., Tamir R., Edenson S., Zhang T.J., Viswanadhan V.N., Toth A., Pearce L.V., Vanderah T.W., Porreca F., Blumberg P.M., Lile J., Sun Y., Wild K., Louis J.C., and Treanor J.J. Molecular determinants of vanilloid sensitivity in TRPV1. J. Biol. Chem. 279 (2004) 20283-20295
211. Bhave G., Hu H.J., Glauner K.S., Zhu W., Wang H., Brasier D.J., Oxford G.S., and Gereau R.W. Protein kinase C phosphorylation sensitizes but does not activate the capsaicin receptor transient receptor potential vanilloid 1 (TRPV1). Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 12480-12485
212. Vlachova V., Teisinger J., Susankova K., Lyfenko A., Ettrich R., and Vyklicky L. Functional role of C-terminal cytoplasmic tail of rat vanilloid receptor 1. J. Neurosci. 23 (2003) 1340-1350
213. Mohapatra D.P., and Nau C. Desensitization of capsaicin-activated currents in the vanilloid receptor TRPV1 is decreased by the cyclic AMP-dependent protein kinase pathway. J. Biol. Chem. 278 (2003) 50080-50090
214. Wilson-Gerwing T.D., Dmyterko M.V., Zochodne D.W., Johnston J.M., and Verge V.M. Neurotrophin-3 suppresses thermal hyperalgesia associated with neuropathic pain and attenuates transient receptor potential vanilloid receptor-1 expression in adult sensory neurons. J. Neurosci. 25 (2005) 758-767
215. Ji R.R., Samad T.A., Jin S.X., Schmoll R., and Woolf C.J. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 36 (2002) 57-68
216. Rashid M.H., Inoue M., Bakoshi S., and Ueda H. Increased expression of vanilloid receptor 1 on myelinated primary afferent neurons contributes to the antihyperalgesic effect of capsaicin cream in diabetic neuropathic pain in mice. J. Pharmacol. Exp. Ther. 306 (2003) 709-717
217. Hong S., and Wiley J.W. Early painful diabetic neuropathy is associated with differential changes in the expression and function of vanilloid receptor 1. J. Biol. Chem. 280 (2005) 618-627
218. Peier A.M., Moqrich A., Hergarden A.C., Reeve A.J., Andersson D.A., Story G.M., Earley T.J., Dragoni I., McIntyre P., Bevan S., and Patapoutian A. A TRP channel that senses cold stimuli and menthol. Cell 108 (2002) 705-715
219. Bandell M., Story G.M., Hwang S.W., Viswanath V., Eid S.R., Petrus M.J., Earley T.J., and Patapoutian A. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradyknin. Neuron 41 (2004) 849-857
220. Sainz I.M., Uknis A.B., Isordia-Salas I., Dela Cadena R.A., Pixley R.A., and Colman R.W. Interactions between bradykinin (BK) and cell adhesion molecule (CAM) expression in peptidoglycan-polysaccharide (PG-PS)-induced arthritis. FASEB J. 18 (2004) 887-889
221. Cruwys S.C., Garrett N.E., Perkins M.N., Blake D.R., and Kidd B.L. The role of bradykinin B1 receptors in the maintenance of intra-articular plasma extravasation in chronic antigen-induced arthritis. Br. J. Pharmacol. 113 (1994) 940-944
222. Burgess G.M., Perkins M.N., Rang H.P., Campbell E.A., Brown M.C., McIntyre P., Urban L., Dziadulewicz E.K., Ritchie T.J., Hallett A., Snell C.R., Wrigglesworth R., Lee W., Davis C., Phagoo S.B., Davis A.J., Phillips E., Drake G.S., Hughes G.A., Dunstan A., and Bloomfield G.C. Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia. Br. J. Pharmacol. 129 (2000) 77-86
223. Rashid M.H., Inoue M., Matsumoto M., and Ueda H. Switching of bradykinin-mediated nociception following partial sciatic nerve injury in mice. J. Pharmacol. Exp. Ther. 308 (2004) 1158-1164
224. Vellani V., Zachrisson O., and McNaughton P.A. Functional bradykinin B1 receptors are expressed in nociceptive neurones and are upregulated by the neurotrophin GDNF. J. Physiol. 560 (2004) 391-401
225. Tonussi C.R., and Ferreira S.H. Bradykinin-induced knee joint incapacitation involves bradykinin B2 receptor mediated hyperalgesia and bradykinin B1 receptor-mediated nociception. Eur. J. Pharmacol. 326 (1997) 61-65
226. Pesquero J.B., Araujo R.C., Heppenstall P.A., Stucky C.L., Silva Jr. J.A., Walther T., Oliveira S.M., Pesquero J.L., Paiva A.C., Calixto J.B., Lewin G.R., and Bader M. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 8140-8145